Share this article
Share this article
COLLEGE STATION, Texas, Dec. 15, 2020 /PRNewswire/ Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft
2 facility will commence in Q4 2020 and will be dedicated to the production of viral vectors used in cell and gene therapies, vaccines and oncolytic products. When completed, the facility will provide Matica Bio s clients with comprehensive viral vector development, manufacturing and analytical services centrally located in one of the fastest-growing biotech regions in the United States.